MX9202030A - Expresion recombinante de subunidades de analogo de exotoxina de colera. - Google Patents

Expresion recombinante de subunidades de analogo de exotoxina de colera.

Info

Publication number
MX9202030A
MX9202030A MX9202030A MX9202030A MX9202030A MX 9202030 A MX9202030 A MX 9202030A MX 9202030 A MX9202030 A MX 9202030A MX 9202030 A MX9202030 A MX 9202030A MX 9202030 A MX9202030 A MX 9202030A
Authority
MX
Mexico
Prior art keywords
colera
exotoxin
recombinant expression
analog subunits
subunits
Prior art date
Application number
MX9202030A
Other languages
English (en)
Inventor
W Neal Barnette
Harvey R Kaslow
Original Assignee
Amgen Inc
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Univ Southern California filed Critical Amgen Inc
Publication of MX9202030A publication Critical patent/MX9202030A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/909—Vibrio

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX9202030A 1991-05-02 1992-04-30 Expresion recombinante de subunidades de analogo de exotoxina de colera. MX9202030A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69473391A 1991-05-02 1991-05-02

Publications (1)

Publication Number Publication Date
MX9202030A true MX9202030A (es) 1993-02-01

Family

ID=24790064

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9202030A MX9202030A (es) 1991-05-02 1992-04-30 Expresion recombinante de subunidades de analogo de exotoxina de colera.

Country Status (18)

Country Link
US (2) US5874287A (es)
EP (1) EP0584284B9 (es)
JP (1) JP3242106B2 (es)
KR (1) KR100249888B1 (es)
CN (1) CN1067679A (es)
AR (1) AR248167A1 (es)
AT (1) ATE199393T1 (es)
AU (1) AU665013B2 (es)
CA (1) CA2102105A1 (es)
DE (1) DE69231708T2 (es)
DK (1) DK0584284T3 (es)
ES (1) ES2156110T3 (es)
GR (1) GR3035724T3 (es)
IL (1) IL101715A (es)
MX (1) MX9202030A (es)
NZ (1) NZ242539A (es)
WO (1) WO1992019265A1 (es)
ZA (1) ZA923162B (es)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043057A (en) * 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6436407B1 (en) 1994-08-26 2002-08-20 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic adjuvant
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
GB9603314D0 (en) * 1996-02-16 1996-04-17 Biocine Spa Immunogenic detoxified mutant toxins
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
ATE421527T1 (de) 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkus b epitopen
WO1999047165A1 (en) * 1998-03-18 1999-09-23 The Administrators Of The Tulane Educational Fund Production of purified mutant enterotoxin for use as an adjuvant
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
EP2261346A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
KR20010088302A (ko) 1998-06-19 2001-09-26 추후 제출 헬리코박터 감염에 대한 비경구 면역화 방법에 있어서의ｌｔ 및 ｃｔ
IL142231A0 (en) * 1998-09-30 2002-03-10 American Cyanamid Co Mutant cholera holotoxin as an adjuvant
BR9916515A (pt) * 1998-12-22 2001-11-06 Thompson Boyce Plant Res Polinucleotìdeo, vetor de expressão, células de e. coli e de agrobacterium tumefaciens transformadas com o vetor de expressão, célula de planta transgênica, semente de planta transgênica, célula eucariótica transgênica, composição imunogênica, método de evocar uma resposta imune em um animal ou ser humano, planta transgênica, e, adjuvante
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
JP2002537102A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
CA2366688A1 (en) 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
EP1272210A1 (en) * 2000-03-17 2003-01-08 The Uab Research Foundation Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediated or humoral immunity
AU2001271268A1 (en) 2000-05-19 2001-12-03 The Administrators Of The Tulane Educational Fund Hybrid lt-a/ct-b holotoxin for use as an adjuvant
EP1315816B1 (en) * 2000-09-08 2010-12-29 University Of Maryland Biotechnology Institute Genetically engineered co-expression dna vaccines, construction methods and uses thereof
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
US20030021766A1 (en) 2001-01-12 2003-01-30 Michael Vajdy Nucleic acid mucosal immunization
EP2277897A1 (en) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
WO2002098369A2 (en) * 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
ATE451386T1 (de) * 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
US20030198621A1 (en) 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
IL163988A0 (en) 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
CA2500661A1 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
EP1585542B1 (en) 2002-12-27 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US9107831B2 (en) 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
US8071652B2 (en) 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
MY144231A (en) 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
SG182163A1 (en) 2003-12-17 2012-07-30 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
MXPA06013448A (es) 2004-05-21 2007-01-23 Wyeth Corp Proteina alterada que liga a la fibronectina en staphylococcus aureus.
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
US8445000B2 (en) 2004-10-21 2013-05-21 Wyeth Llc Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
CN101072585A (zh) 2004-11-01 2007-11-14 诺华疫苗和诊断公司 产生免疫应答的组合方法
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8926993B2 (en) 2006-07-17 2015-01-06 Aduro Biotech Methods and compositions using Listeria for enhancing immunogenicity by prime boost
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
CA2736799A1 (en) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
JP2012508174A (ja) 2008-11-05 2012-04-05 ワイス・エルエルシー β溶血性連鎖球菌（ＢＨＳ）疾患を予防するための多成分免疫原性組成物
CA2743306A1 (en) 2008-11-12 2010-05-20 Theraclone Sciences, Inc. Human m2e peptide immunogens
CN105056229A (zh) 2009-01-05 2015-11-18 埃皮托吉尼西斯股份有限公司 佐剂组合物及使用方法
CA2754896C (en) 2009-03-09 2017-11-28 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
CN102596243B (zh) 2009-06-16 2015-10-21 密执安大学评议会 纳米乳剂疫苗
US9161974B2 (en) 2010-05-23 2015-10-20 Aduro Biotech, Inc. Methods and compositions using listeria for adjuvant treatment of cancer
EP3170508B1 (en) 2010-06-04 2019-11-13 Wyeth LLC Vaccine formulations
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
AU2011294776B2 (en) 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
SE535625C2 (sv) * 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
CA2834349A1 (en) 2011-04-26 2012-11-01 Molecular Express, Inc. Liposomal formulations
CA2839507A1 (en) 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
MX2014005548A (es) 2011-11-14 2014-08-21 Novartis Ag Complejos inmunogenicos de carbomeros polianionicos y polipeptidos env y metodos de manufactura y usos de los mismos.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
US9732144B2 (en) 2012-07-05 2017-08-15 Ohio State Innovation Foundation Infectious bursal disease (IBDV) vaccine compositions
CN104854128A (zh) 2012-07-19 2015-08-19 硕腾有限责任公司 牛流感病毒组合物
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
MX363511B (es) 2012-08-16 2019-03-26 Pfizer Proceso de glucoconjugación y composiciones.
PL2912186T3 (pl) 2012-10-24 2021-06-14 Platelet Targeted Therapeutics Llc Leczenie ukierunkowane na płytki krwi
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
AU2014234982A1 (en) 2013-03-15 2015-09-24 Zoetis Services Llc Cross-protection of bovines against B. trehalosi infection by a multi-valent vaccine
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
WO2015063611A2 (en) 2013-11-01 2015-05-07 University Of Oslo Albumin variants and uses thereof
EP3068426B1 (en) 2013-11-13 2020-02-12 University Of Oslo Outer membrane vesicles and uses thereof
DK3069138T3 (en) 2013-11-15 2019-04-08 Univ Oslo Hf CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
AU2015208820B2 (en) 2014-01-21 2020-05-14 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
PL3583947T3 (pl) 2014-01-21 2024-04-02 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
EP3104886B1 (en) 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
EP4112076A1 (en) 2014-10-10 2023-01-04 The Regents of The University of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
US10624964B2 (en) 2015-05-01 2020-04-21 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs
MX2018001841A (es) 2015-08-14 2018-08-01 Zoetis Services Llc Composiciones de mycoplasma bovis.
CN108348593B (zh) 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
EP3402878A1 (en) 2016-01-11 2018-11-21 Zoetis Services LLC Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
US11319383B2 (en) 2016-03-14 2022-05-03 Universitetet | Oslo Engineered immunoglobulins with altered FcRn binding
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
EP3269385A1 (en) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
MX2019009011A (es) 2017-01-31 2019-09-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos.
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
WO2018183666A1 (en) 2017-03-31 2018-10-04 Boston Medical Center Corporation Methods and compositions using highly converved pneumococcal surface proteins
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
JP2020533338A (ja) 2017-09-07 2020-11-19 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ ワクチン分子
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
EP3574915A1 (en) 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
EP4003410A1 (en) 2019-07-31 2022-06-01 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
US20230338530A1 (en) 2020-01-10 2023-10-26 Lg Chem, Ltd. Composition comprising antigen-presenting cell co-expressing mhc and tumor antigen, and cancer treatment using same
AU2021211012A1 (en) 2020-01-24 2022-08-25 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
US20230233652A1 (en) 2020-04-16 2023-07-27 Par'immune Sas 28 kda gst proteins from schistosoma for the treatment of vasculitis
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
IL301402A (en) 2020-09-17 2023-05-01 Inst Nat Sante Rech Med An immunogenic product containing a segment of ige for the treatment of inflammatory disorders mediated by ige
US20240156935A1 (en) 2021-03-31 2024-05-16 Vib Vzw Vaccine Compositions for Trypanosomatids
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328209A (en) * 1979-04-11 1982-05-04 Board Of Regents, The University Of Texas System Cholera vaccine
US4666837A (en) * 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
US4935364A (en) * 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
US4882278A (en) * 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants

Also Published As

Publication number Publication date
IL101715A0 (en) 1992-12-30
DK0584284T3 (da) 2001-06-18
US5874287A (en) 1999-02-23
ATE199393T1 (de) 2001-03-15
EP0584284A4 (en) 1995-03-15
DE69231708D1 (de) 2001-04-05
EP0584284A1 (en) 1994-03-02
NZ242539A (en) 1993-11-25
JPH06507551A (ja) 1994-09-01
GR3035724T3 (en) 2001-07-31
EP0584284B9 (en) 2002-11-13
WO1992019265A1 (en) 1992-11-12
DE69231708T2 (de) 2001-07-05
AU2293092A (en) 1992-12-21
AR248167A1 (es) 1995-06-30
AU665013B2 (en) 1995-12-14
US5770203A (en) 1998-06-23
ZA923162B (en) 1993-04-28
JP3242106B2 (ja) 2001-12-25
EP0584284B1 (en) 2001-02-28
IL101715A (en) 2005-06-19
CA2102105A1 (en) 1992-11-03
KR100249888B1 (ko) 2000-04-01
ES2156110T3 (es) 2001-06-16
CN1067679A (zh) 1993-01-06

Similar Documents

Publication Publication Date Title
MX9202030A (es) Expresion recombinante de subunidades de analogo de exotoxina de colera.
DE68924111D1 (de) UV-härtbare Siloxanzusammensetzung enthaltend einen Haftver- mittler.
NO924395L (no) Rekombinante menneske-faktor viii derivater
FR2676917B1 (fr) Prothese de cheville.
FI941398A0 (fi) Modifioituja peptidijohdannaisia
ATE190066T1 (de) Neuartige peptidderivate
FI921740A0 (fi) Hybrid polypeptid.
FI892714A (fi) Rekombinant-coccidiosisvaccin.
DE59300297D1 (de) Vernetzbare Zusammensetzung auf Aminosiliconbasis.
FI923280A0 (fi) Aminosubstituerade piperazinderivat.
ES2076999T3 (es) Peptidos anticoagulantes radiomarcados.
DK162890D0 (da) Polypeptid
FI890851A0 (fi) Arrangemang foer bestaemning av positionerna foer olika segment hos en arm.
MX9205003A (es) Derivados novedosos de benzopirano.
DE68908280D1 (de) Analogschalter.
DE69204411D1 (de) Überzugszusammensetzung.
FR2684291B1 (fr) Prothese de cheville.
FR2712467B3 (fr) Structure pour branche de parapluie.
MX9200872A (es) Composicion de bis-bibenzimidazol.
MX9200697A (es) Sistema de expresion de entomopoxvirus.
FI920845A0 (fi) Farmaceutiska kompositioner innehaollande interleukin-2.
IT1266849B1 (it) Programmatore analogico perfezionato per forni.
DE59105006D1 (de) Carboxylgruppenhaltige Cyclohexanderivate.
IT1264129B1 (it) Peptidi ad attivita' immunomodulatoria derivati da frammenti di leucochinina
MX9202293A (es) Composicion de vacuna no-irritante.